
Sign up to save your podcasts
Or


Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.
By American Academy of Neurology4.6
2121 ratings
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.

43,837 Listeners

299 Listeners

26 Listeners

10 Listeners

53 Listeners

87,868 Listeners

7,244 Listeners

134 Listeners

9 Listeners

6 Listeners

16,525 Listeners

38 Listeners

11,013 Listeners

589 Listeners

80 Listeners